In a breast cancer cohort, a pre-treatment high CD4+/CD8+ ratio was an independent predictor of pathological complete response after neo-adjuvant chemotherapy and was associated with better prognosis (García-Martínez et al, 2014) as was the presence of CD20+ B-cells (Brown et al, 2014). The gene discussed is CD8A; the disease is breast carcinoma.